CYC116 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a potent inhibitor of Aurora kinases and VEGFR2, which are key regulators of cell division and angiogenesis, respectively. By targeting these pathways, CYC116 aims to disrupt the proliferation of cancer cells and inhibit the formation of new blood vessels that supply tumors, thereby limiting their growth and spread. Its application is particularly relevant in the context of solid tumors and hematological malignancies, where uncontrolled cell division and angiogenesis play critical roles in disease progression. Research is ongoing to evaluate its efficacy and safety in preclinical and clinical settings, with the goal of developing it as a targeted anticancer therapy.